|
Q1 FY2027
As of Jul 31, 2026
|
Q4 FY2026
As of Apr 30, 2026
|
Q3 FY2026
As of Jan 31, 2026
|
Q2 FY2026
As of Oct 31, 2025
|
Q1 FY2026
As of Jul 31, 2025
|
Q4 FY2025
As of Apr 30, 2025
|
Q3 FY2025
As of Jan 31, 2025
|
Q2 FY2025
As of Oct 31, 2024
|
Q1 FY2025
As of Jul 31, 2024
|
Q4 FY2024
As of Apr 30, 2024
|
Q3 FY2024
As of Jan 31, 2024
|
Q2 FY2024
As of Oct 31, 2023
|
Q1 FY2024
As of Jul 31, 2023
|
Q4 FY2023
As of Apr 30, 2023
|
Q3 FY2023
As of Jan 31, 2023
|
Q2 FY2023
As of Oct 31, 2022
|
Q1 FY2023
As of Jul 31, 2022
|
Q4 FY2022
As of Apr 30, 2022
|
Q3 FY2022
As of Jan 31, 2022
|
Q2 FY2022
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| TOTAL CURRENT ASSETS | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| TOTAL CURRENT LIABILITIES | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Note payable | ||||||||||||||||||||
| TOTAL LIABILITIES, ALL CURRENT | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Series B Convertible Preferred Stock, $0.0001 stated value per share, 6,000 designated; 2,100 and nil 0 issued and outstanding as of April 30, 2024 and April 30, 2023, respectively | ||||||||||||||||||||
| Series D Convertible Preferred Stock, $0.0001 par value, $1,000 stated value per share, 25,000 and 0 nil shares designated; 7,500 and 0 nil issued and outstanding as of July 31, 2026 and April 30, 2026, respectively | ||||||||||||||||||||
| Common stock, $0.0001 par value: 300,000,000 shares authorized; 4,825,723 and 4,256,039 issued and outstanding as of July 31, 2026 and April 30, 2026, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Note receivable for common stock – related party | ||||||||||||||||||||
| Subscription receivable for preferred stock – related party | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Total subscription receivable for preferred stock – related party | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| TOTAL STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
Loading...
